

Fig. 5: Estimated US Patent Expirations through 2018

Brand	Company	Indication	Expiry
Aranesp	Amgen	Anemia	2014
Celebrex	Pfizer	Pain	2014
Copaxone	Teva	Multiple sclerosis	2014
Evista	Eli Lilly	Osteoporosis	2014
Gleevec	Novartis	Oncology	2014
Intuniv	Shire	ADHD	2014
Lunesta	Sunovion	Insomnia	2014
Nasonex	Merck	Allergies	2014
Nexium	AstraZeneca	Heartburn	2014
Rituxan	Roche	Oncology/RA	2014
Abilify	BMS/Otsuka	Depression/bipolar	2015
Avodart	GlaxoSmithKline	BPH	2015
Lantus	Sanofi	Diabetes	2015
Namenda	Forest	Alzheimer's disease	2015
Neulasta	Amgen	Neutropenia	2015
Premarin	Pfizer	Menopausal symp.	2015
Symbicort	AstraZeneca	Asthma/COPD	2015
Zyvox	Pfizer	Infection	2015
Benicar	Daiichi Sankyo	Hypertension	2016
Crestor	AstraZeneca	Atherosclerosis	2016
Humira	AbbVie	RA/Crohn's/psoriasis	2016
Prezista	J&J	HIV	2016
Zytiga	Janssen	Cancer	2016
Alimta	Eli Lilly	Cancer	2017
Cialis	Eli Lilly	Erectile dysfunction	2017
Reyataz	Bristol-Myers Squibb	HIV	2017
Seroquel - all	AstraZeneca	Schizophrenia	2017
Vytorin	Merck	Cholesterol	2017
Zetia	Merck	Cholesterol	2017
Nuvaring	Merck	Contraception	2018
Pulmicort	AstraZeneca	Asthma	2018
Ritalin/Focalin	Novartis	ADHD	2018
Tarceva	Roche	Oncology	2018
Vesicare	Astellas	OAB	2018
Xolair	Novartis/Roche	Asthma	2018

Source: Barclays Research